Michelle Beckham, MD
Family Medicine · Spring Hope, NCNPI 1417941402
Payments from drug & device makers
Across 245 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$898
- GSK$517
- Novo Nordisk$427
- Lilly USA, LLC$427
- Amgen$348
- AstraZeneca$337
- plus $853 from 21 others
What the payments were for
- Food & beverage$3,795100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $898 |
| GSK | 31 | $517 |
| Novo Nordisk | 24 | $427 |
| Lilly USA, LLC | 23 | $427 |
| Amgen | 27 | $348 |
| AstraZeneca | 21 | $337 |
| Novartis | 7 | $116 |
| Boehringer Ingelheim | 7 | $111 |
| Bayer | 5 | $89 |
| Sumitomo Pharma America, Inc. | 4 | $76 |
| Exact Sciences | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Pfizer | 3 | $44 |
| Kyowa Kirin, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Lundbeck LLC | 1 | $27 |
| Astellas Pharma US Inc | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Organon | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
How this compares
$3,807 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 122 | $109,943 |
| FarxigaDapagliflozin Propanediol | 126 | $100,144 |
| EliquisApixaban | 117 | $100,022 |
| OzempicSemaglutide | 82 | $96,113 |
| RybelsusSemaglutide | 41 | $70,118 |
| LinzessLinaclotide | 90 | $62,078 |
| MounjaroTirzepatide | 55 | $61,950 |
| XareltoRivaroxaban | 73 | $50,585 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $46,737 |
| TrulicityDulaglutide | 40 | $45,091 |
| Repatha SureclickEvolocumab | 67 | $42,887 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $28,610 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $16,039 |
| QuliptaAtogepant | 13 | $14,284 |
| EntrestoSacubitril/Valsartan | 17 | $14,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $427 | $166,230123 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $111 | $133,387157 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $337 | $131,279178 claims |
| Lilly USA, LLCMounjaro, Trulicity | $427 | $107,04195 claims |
| PfizerEliquis, Premarin | $44 | $103,442129 claims |
| AbbVieLinzess, Qulipta, Creon | $898 | $83,426114 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $517 | $63,286104 claims |
| Johnson & JohnsonXarelto | $14 | $50,58573 claims |
| NovartisEntresto | $116 | $14,18017 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $76 | $13,44218 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $10,58414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Spring Hope
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.